Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk.
2016 (English)In: European Journal of Preventive Cardiology, ISSN 2047-4873, E-ISSN 2047-4881, Vol. 23, no 3, 275-281 p.Article in journal (Refereed) Published
Clinical guidelines should be based on the best available evidence and are of great importance for patient care and disease prevention. In this respect, the 2013 American College of Cardiology/American Heart Association report is highly appreciated and well-recognized. The report included critical questions concerning hypercholesterolaemia, but its translation into a clinical guideline initiated intense debate worldwide because of the recommendation to switch from a treat-to-target approach for low-density-lipoprotein-cholesterol to a statin dose-based strategy.
Place, publisher, year, edition, pages
2016. Vol. 23, no 3, 275-281 p.
Hypercholesterolaemia; cardiovascular prevention
Cardiac and Cardiovascular Systems
IdentifiersURN: urn:nbn:se:liu:diva-124057DOI: 10.1177/2047487314567001ISI: 000369526800006PubMedID: 25595550OAI: oai:DiVA.org:liu-124057DiVA: diva2:895593
Funding agencies:DMW: personal fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Merck Sharpe and Dohme, Novartis, Roche, Sanofi, Bayer, Janssen-Cilag, Lilly, NovoNordisk; non-financial support from Sanofi Germany, outside the submitted work. GA, RC, JD, EF, HG, AGO, WFR, ES: none. AVE: personal fees from Amgen Switzerland, Astra Zeneca Switzerland, Merck Sharpe and Dohme Switzerland, Sanofi Aventis, outside the submitted work; and member of the Executive Board of the European Atherosclerosis Society as well as the president of the Swiss Working Group on Lipids and Atherosclerosis (= Swiss Atherosclerosis Society), which both published own recommendations for the prevention of heart disease by lipid-lowering therapy.2016-01-192016-01-192016-03-03